MedPath

Telephone-Based Genetic Counseling or Standard Genetic Counseling in Women at Risk of Carrying the BRCA1 or BRCA2 Mutation

Not Applicable
Completed
Conditions
Breast Cancer
Interventions
Behavioral: Usual Care
Behavioral: Telephone Genetic Counseling
Registration Number
NCT00287898
Lead Sponsor
Georgetown University
Brief Summary

RATIONALE: Genetic counseling may work as well over the telephone as it does in-person. It is not yet known whether genetic counseling by telephone is more effective than standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.

PURPOSE: This randomized phase III trial is studying telephone-based genetic counseling to see how well it works compared to standard (in-person) genetic counseling in women at risk of carrying the BRCA1 or BRCA2 mutation.

Detailed Description

OBJECTIVES:

Primary

* Compare the impact of telephone genetic counseling (TGC) versus standard genetic counseling (SGC) on utilization of BRCA1/BRCA2 testing in women at risk of carrying the BRCA1/BRCA2 mutation.

* Compare the relative efficacy of TGC versus SGC on satisfaction with the counseling process, informed decision making, psychosocial distress, and quality of life.

Secondary

* Identify participant characteristics that predict differential response to TGC.

* Explore the mechanisms by which TGC or SGC impact distress and quality of life.

OUTLINE: This is a randomized, multicenter study. Participants are stratified according to participating site. Participants are randomized to 1 of 2 groups.

* Group 1 (standard genetic counseling): Participants undergo an in-person genetic counseling session. Participants are then given the option of providing blood for genetic testing at the study site. Participants who choose to undergo genetic testing receive their results in-person from their genetic counselor.

* Group 2 (telephone-based genetic counseling): Participants undergo a telephone-based genetic counseling session. Participants who choose to undergo genetic testing receive a pre-labeled blood kit in the mail. Participants receive their results over the phone from their genetic counselor.

After completion of genetic counseling, all participants are followed periodically for 1 year.

PROJECTED ACCRUAL: A total of 600 participants will be accrued for this study.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
669
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Usual CareUsual CareParticipants randomized to usual care will receive standard in-person genetic counseling.
Telephone Genetic CounselingTelephone Genetic CounselingParticipants randomized to this arm will receive all genetic counseling via telephone.
Primary Outcome Measures
NameTimeMethod
Uptake of BRCA1/BRCA2 mutation testing as measured by genetic test results at 3 and 6 months6 months
Knowledge assessed by genetic testing knowledge measure at post-counseling and 3 months3 months
Decision making as assessed by Decisional Conflict Satisfaction at post-counseling and 3 months3 months
Distress as assessed by Impact of Events Scale Brief Symptom Inventory MICRA at 3 and 6 months6 months
Quality of life as assessed by SF-12 health survey at 3 and 6 months6 months
Secondary Outcome Measures
NameTimeMethod
Costs by cost measurement post-counseling6 months
Management behaviors as assessed by utilization of management options (e.g., mammography, surgery, and chemoprevention) at 6 and 12 months12 months

Trial Locations

Locations (4)

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center

🇺🇸

Washington, District of Columbia, United States

Mount Sinai School of Medicine

🇺🇸

New York, New York, United States

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

🇺🇸

Boston, Massachusetts, United States

Vermont Cancer Center at University of Vermont

🇺🇸

Burlington, Vermont, United States

© Copyright 2025. All Rights Reserved by MedPath